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1. Introduction 
Alzheimer’s disease (AD) is a severe senile type of dementia that affects a large number of 
elderly people. It is estimated that 5.4 million people in the worldwide are affected by this 
disease in 2011 and this number continues to grow yearly. AD is characterized by profound 
memory loss and severe cognitive decline. The pathological hallmarks of AD are the 
presence of numerous extracellular deposits termed senile plaques and intraneuronal 
neurofibrillary tangles (NFTs) (Selkoe, 1991). The selective loss of synapses and neurons is 
observed in the brain of patients, and this decrease in the number of synapses is strongly 
correlated with memory impairment (Terry et al., 1991). The major component of NFTs is 
the phosphorylated tau protein, while β-amyloid protein (AβP) is the major component of 
senile plaques.  
Although the pathological cause of AD has not yet strictly been elucidated, numerous 
biochemical, toxicological, cell biological, and genetic studies have supported the “amyloid 
cascade hypothesis”, which suggests that the neurotoxicity and synaptotoxicity (synaptic 
degeneration) caused by AβP play a central role in AD (Hardy & selkoe, 2002). Moreover, 
oligomerization and conformational changes in AβP are important for its neurodegenerative 
capacity. 
There is considerable interest regarding the mechanism by which AβPs cause 
neurodegeneration. AβPs reportedly cause numerous adverse effects on neuronal survival, 
e.g., reactive oxygen species (ROS) production, cytokine induction, endoplasmic reticulum 
(ER) stresses induction, and the abnormal increase in intracellular Ca2+ levels ([Ca2+]i) (Small 
et al., 2001). These adverse effects are complex and may be interwoven. Among them, the 
disruption of Ca2+ homeostasis could be the primary event in the pathogenesis of AD, since 
Ca2+ ions play critical roles in the function and structure of neurons and other cells. 
Increasing evidence suggests the implications of Ca2+ dyshomeostasis in the pathogenesis of 
AD (Green and LaFerla, 2008; Demuro et al., 2010).  
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Several possible mechanisms account for AβP-induced Ca2+ dyshomeostasis, e.g., its 
interaction with endogenous Ca2+-permeable ion channels, disruption of membrane 
integrity, and the formation of Ca2+ permeable channels (pores) by the direct incorporation 
of AβP into membranes.  Here, we focus on the ‘amyloid channel hypothesis’ (Arispe et al., 
2007; Lin et al. 2001; Kawahara, 2011b), namely, that the direct incorporation of AβPs and 
the subsequent imbalances of Ca2+ and other ions through amyloid channels may be the 
primary event in AßP neurotoxicity.  
In this chapter, we review the current understanding of the link between Ca2+ homeostasis 
and AD pathogenesis based on the amyloid channel hypothesis the characteristics of AβP-
induced neurotoxicity and synaptotoxicity caused by Ca2+ dyshomeostasis via amyloid 
channels. We also discuss the possible development of new drugs for the treatment and 
prevention of AD by attenuating amyloid channels and inhibiting AβP-induced Ca2+ 
dyshomeostasis.  
2. Amyloid cascade hypothesis 
AβP is a small peptide with 39–43 amino acid residues. It is derived from the proteolytic 
cleavage of a large precursor protein (amyloid precursor protein; APP) by the cleavage of its 
N-terminal by β-secretase (BACE), followed by the intra-membrane cleavage of its  
C-terminal by γ-secretase. There are several species of AβP, such as AβP(1–40), the first 40 
amino acid residues, or AβP(1–42), which are generated by the different cleavage processes 
in its C-terminal domain. Genetic studies of early-onset cases of familial AD indicated that 
APP mutations and the consequent changes in AβP metabolism are associated with AD 
(Goate et al., 1991). Moreover, mutations in the presenilin genes also account for the 
majority of cases of early-onset familial AD (Sherrington et al., 1995). Presenilins have been 
identified as one of γ -secretase proteins, and their mutations also influence the production 
of AβP and its neurotoxicity (Selkoe and Wolfe, 2007). 
Yankner et al. reported that AβP(1–40) caused the death of cultured rat hippocampal 
neurons and the neurodegeneration in the brains of experimental animals (Yankner et al., 
1991). A smaller fragment of AβP (AβP (25–35)) or a longer variant (AβP (1–42)) were also 
reported to cause neuronal death. AβP is a hydrophobic peptide with an intrinsic tendency 
to self-assemble to form sodium dodecyl sulfate (SDS)-stable oligomers. In an aqueous 
solution, freshly prepared and dissolved AβP exists as a monomeric protein with a random 
coil structure. However, following incubation at 37۫ºC for several days (aging), AβPs form 
aggregates (oligomers) with β-pleated sheet structures, and finally form insoluble 
aggregates, termed amyloid fibrils (Fig. 1). Pike et al. revealed that aged AβP(1–40) peptides 
were considerably more toxic to cultured neurons than fresh (freshly prepared just before the 
experiment) AβP(1–40) (Pike et al, 1991). The ß-sheet content of AßP solutions, as 
determined by circular dichroism (CD) spectroscopy, correlates with its neurotoxicity 
(Simmons et al., 1994). Jarrett and Lansbury demonstrated that the longer peptide variant, 
AβP(1–42), polymerizes much quicker than AβP(1–40) (Jarrett and Lansbury, 1993). AβP(1–
42) enhances the aggregation of AβP(1–40) and functions as a “seed” for amyloid fibrils. 
AβP (1–42) is more abundant in the brains of AD patients than in age-matched controls. The 
point mutations of APP are located near the γ-secretase cleavage-site and influences the ratio 
of AβP(1–40) and AβP(1–42). Mutations of APP and the presenilin genes increase the 
production of AβP (1–42) in the transfected cell lines.  
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Recent studies on the identified AβP species further strengthened and refined the amyloid 
cascade hypothesis. Approaches using size-exclusion chromatography, gel electrophoresis, 
and atomic force microscopy (AFM) have demonstrated that there are several stable types of 
oligomers: naturally occurring soluble oligomers (dimers or trimers), AßP-derived diffusible 
ligands (ADDLs), AβP globulomers, and protofibrils. Walsh et al. found the existence of 
SDS-stable oligomers in the conditioned medium of cultured cells transfected with the 
human APP gene. The intracerebral administration of these SDS-stable low-molecular-
weight oligomers (dimers, trimers, or tetramers) inhibited long-term potentiation (LTP), 
which is a form of synaptic information storage that is a well-known paradigm for the 
mechanisms underlying memory formation (Walsh and Selkoe, 2007). They also 
demonstrated that LTP was not blocked by AβP monomers or larger aggregates. Natural 
AβP oligomers derived from the cerebrospinal fluid of AD patients induced the loss of 
dendritic spines and synapses, and also blocked the oligomers in the conditioned medium. 
Klein and the colleagues reported that ADDLs obtained by sedimentation with clusterin are 
highly toxic to cultured neurons. They also reported that ADDLs inhibited LTP and 
exhibited adverse effects on synaptic plasticity e.g., decreased spine density, abnormal spine 
morphology, and decreased levels of synaptic proteins (Lacor et al., 2007). Tomiyama et al. 
found a new AβP variant (AβP E42Δ) that exhibited enhanced oligomerization but no 
fibrillization (Tomiyama et al., 2008). This unique variant AβP decreased synaptophysin 
immunostaining and blocked LTP. Since synaptic plasticity is crucial for the process of 
memory formation and is involved in the early stages of AD, these lines of evidence indicate 
that the synaptic impairment induced by AβP oligomers is the primary event in the memory 
impairment observed in AD patients. 
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Fig. 1. Oligomerization of AβP 
AβP monomers exhibit random-coil structures. However, during aging or in the presence of 
some acceleratory factors, AβP self-aggregates and forms several types of oligomers (SDS-
soluble oligomers, ADDLS, globulomers, protofibrils, etc.) and finally forms insoluble 
aggregates, which are termed amyloid fibrils. Oligomeric soluble AβPs are toxic, although 
monomers and fibrils are rather nontoxic. 
www.intechopen.com
 
Advanced Understanding of Neurodegenerative Diseases 
 
118 
AβP is secreted into the cerebrospinal fluid (CSF) of young individuals as well as in aged or 
dementia patients (Fukuyama et al., 2000). Therefore, factors that accelerate or inhibit AβP 
oligomerization may play essential roles in the pathogenesis of AD. Several factors such as 
peptide concentration, the pH or composition of solvents, and temperature can influence the 
oligomerization processes. In addition, oxidations, mutations, and racemization of AβP 
enhance its oligomerization. Substances that can influence the oligomerization processes, 
e.g., cholesterol or its oxidation products, transthyretin, rifampicin, curcumin, aspirin, 
docosahexaenoic acid (DHA) and peptides such as the β-sheet breaker peptide, reportedly 
inhibit AβP oligomerization in vitro.  
Among these factors, Al is of particular interest considering its epidemiological link with 
AD (Kawahara and Kato-Negishi, 2011). Al3+ has strong positive charges and a relatively 
small ionic radius in comparison to other metal ions; thus, Al3+ firmly binds to metal-
binding amino acids (e.g. histidine, tyrosine, arginine etc.) or phosphorylated amino acids 
and acts as a cross-linker. Owing to this property, Al can cause the aggregation of various 
proteins and induce the conformational changes. Exposure to Al causes the accumulation of 
AβP in cultured neurons and in the brains of experimental animals and humans (Pratico et 
al., 2002; Exley and Esiri, 2006). 
3. Alzheimer’s Disease and calcium homeostasis  
Ca2+ is required for various normal brain functions and is a component of key enzymes such 
as kinases, phosphatases, and proteases, it is highly possible that Ca2+ dyshomeostasis could 
be the earliest adverse event among AβP-induced various adverse effects such as ROS 
production, cytokine induction, endoplasmic reticulum (ER) stresses induction. Once 
neuronal Ca2+ homeostasis is disrupted and [Ca2+]i is changed, various apoptotic pathways, 
such as Ca2+-activated neutral protease (calpain) and caspase, are activated, leading to 
neuronal death. The disruption of Ca2+ homeostasis can trigger membrane disruption, the 
formation of free radicals, and the induction of other adverse effects, which are often 
observed after exposure to AβP. It is widely recognized that an increase in [Ca2+]i induces 
changes in the number and morphology of synapses and spines, and that an imbalances of 
Ca2+ in synapses directly influences neuronal activity and synaptic impairment. Considering 
that APP localizes in synapses and that AβP is secreted from APP into synaptic clefts by 
neuronal excitation, the adverse effects caused by AβP-induced Ca2+ dyshomeostasis can 
occur in synaptic compartments and induce synaptotoxicity. Therefore, the influx of Ca2+ is 
tightly controlled and [Ca2+]i levels are strictly regulated by various mechanisms including 
voltage-dependent Ca2+ channels (VDCC), and neurotransmitter receptors e.g., glutamate 
(Glu) and acetylcholine (ACh) (Zorumski and Thio, 1992). Moreover, the ER and 
mitochondoria represent the major intracellular stores of Ca2+ (Green and LaFerla, 2008; 
Leuner et al., 2007).  
An increasing amount of data indicates that exposure to AβP causes an abnormal increase in 
[Ca2+]i in intoxicated neurons. There is considerable interest regarding the mechanism by 
which AβPs interact with neurons and disrupts Ca2+ homeostasis (Demuro et al., 2010). 
There are several possible mechanisms that account for AβP-induced Ca2+ dyshomeostasis, 
e.g., interaction with endogenous Ca2+-permeable ion channels, disruption of membrane 
integrity, and formation of Ca2+-permeable channels (pores) by the direct membrane 
incorporation of AβP (Fig.6). It is possible that AβP directly binds to membranes and causes 
their disruption, or that AβP-induced ROS impairs membrane structures. 
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Fig. 2. AβP-induced calcium dyshomeostasis in neurons. It is possible that AßP-induced 
Ca2+ dyshomeostasis by (i) its interactions with endogenous Ca2+-permeable ion channels, 
(ii) disruption of membrane integrity, and (iii) formation of Ca2+ permeable channels (pores) 
by the direct membrane incorporation of AβP. AβP can directly cause membrane disruption, 
or AβP-induced ROS can impair membrane structure. Presenilins in the ER or mitochondria 
can participate in the abnormal increase in [Ca2+]i in neurons 
AβP reportedly binds to N-methyl D-aspartate (NMDA)-, and α-amino-3-hydroxy-5-
methylisoxazole-4-propionic acid (AMPA) -type glutamate receptors (Parameshwaran et al., 
2008), and nicotinic ACh receptors (Parri and Dineley, 2010). All of these receptors contain 
Ca2+ channels and regulate [Ca2+]i during membrane depolarization. AβP also influences 
voltage-gated Ca2+ channels and the inositol triphosphate (IP3) receptor. The influx of Ca2+ 
from the ER is regulated by ryanodine-type Ca2+ channels, the sarcoplasmic reticulum Ca-
ATPase (SERCA), and presenilins (Green et al., 2008). Presenilins are found in the ER 
membrane, and are involved in capacitative Ca2+ entry, ER Ca2+ signaling, Ca2+ leakage from 
the ER, and mitochondrial Ca2+ signaling (Querfurth and LaFerla, 2010).  
4. Formation of Ca
2+
 permeable pores by AßP 
Our and other numerous studies have demonstrated that AβPs are directly incorporated 
into the surfaces of cellular membrane and create unregulated cytotoxic pore-like channels. 
In 1993, Arispe et al. first demonstrated that AβP(1–40) directly incorporates into artificial 
lipid bilayer membranes and forms cation-selective ion channels (Arispe et al., 1993a, 
1993b). These channels termed amyloid channels were revealed to be giant multilevel pores 
that can facilitate the transport of large amounts of Ca2+. Their activity was blocked by Zn2+ 
ions, which are abundant in the brain (Arispe et al., 1996). Electrophysiological studies 
have revealed that other neurotoxic peptide fragments of AβP including AβP(25–35) and 
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AβP(1–42) form Ca2+-permeable pores in artificial lipid bilayers. The C-terminal fragment 
of APP (CT105) including AβP also formed ion channels in Xenopus oocytes (Fraser et al., 
1996).  
Durell et al. proposed a 3-D structural model of amyloid channels obtained from a computer 
simulation of the secondary structure of AβP(1–40) in membranes that showed the 
aggregation of 5- to 8-mers to form pore-like structures on the membranes (Durell et al., 
1994). Jang et al. established a model for amyloid channels on membranes and observed the 
pentameric AβP forms pores (Jang et al, 2009). Strodel et al. proposed a model of AβP(1–42) 
pores which consist of tetrameric and hexameric β-sheet subunits from the observations in 
NMR (Strodel et al., 2010). The dimension, shape, and subunit organization of these models 
were in good agreement with the morphological observations using high resolution AFM 
that demonstrated that AβPs form pore-like structures on mica plates or on reconstituted 
membranes (Lal et al., 2007, Jang et al., 2010). Furthermore, the presence of pore-like 
structures of AßPs in vivo was demonstrated in the neuronal cell membrane of the brains of 
AD patients and of AD-model mice. Using high resolution transmission electron 
microscopy, Inoue observed in situ AßP pores in the neuronal cell membrane in AD brains 
(Inoue, 2008). Kayed et al. reported that the annular protofibrils (APFs) of AßP exhibit ring-
shaped and pore-like structures (Kayerd, et al., 2009). The age-dependent accumulation of 
APFs was observed on the membranes of AD model mice (APP transgenic mice; APP23) 
(Kokubo et al., 2009).  
It is important to determine whether AβPs form channels in neuronal cell membranes in 
addition to artificial lipid bilayers. To address this issue, we employed membrane patches 
from a neuroblastoma cell line (GT1-7 cells), and found that AβP(1–40) formed amyloid 
channels on GT1-7 cell membranes (Kawahara et al., 1997). GT1-7 cells (immortalized 
hypothalamic neurons) are derived from murine hypothalamic neurons by site-directed 
tumorigenesis and exhibit several neuronal characteristics such as the extension of neurites 
and the expression of neuron-specific proteins and receptors (Mellon et al., 1990). The 
features of amyloid channels formed on GT1-7 membranes were considerably similar to 
those observed in artificial lipid bilayers; cation-selective, multilevel, voltage-independent, 
and long-lasting; channel activity was inhibited by the addition of Zn2+, and recovered by 
the addition of zinc chelator o-phenanthroline. Moreover, Sepulveda et al. revealed that 
AβP(1-40) formed perforations on membranes excised from hippocampal neurons and 
induced currents (Sepulveda et al., 2010). The effect of AβP was similar to that of gramicidin 
and amphotericin which are commonly used to perforate neuron membranes. 
Furthermore, we have revealed that AβP directly caused the disruption of liposomal 
membrane vesicles by observing the release of fluorescent dye (Kawahara et al., 2011b). 
These results are consistent with the findings that AßP causes membrane disruption, 
increases membrane permeability, causes hemolysis, and changes membrane fluidity 
(Eckert et al., 2005).  
These results strongly support the hypothetical idea termed amyloid channel hypothesis 
namely, that the direct incorporation of AβPs and the subsequent imbalances of Ca2+ and 
other ions through amyloid channels may be the primary event in AßP neurotoxicity. 
5. Disruption of calcium homeostasis by amyloid channels 
In order to test the validity of the amyloid channel hypothesis more precisely, we examined 
whether AβP alters the [Ca2+]i levels of GT1-7 cells under the same conditions, using a high- 
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resolution multi-site video imaging system with Ca2+-sensitive fluorescent dye (fura-2) 
(Kawahara et al., 2000; Kawahara & Kuroda, 2001). We also observed AβP-induced 
abnormal increases in [Ca2+]i in primary cultured rat hippocampal neurons (Kato-Negishi & 
Kawahara, 2008). Shown in figure 3 are temporal changes of [Ca2+]i in GT1-7 cells before and 
after exposure to AβP(1-40) and related peptides. Although a marked increase in [Ca2+]i was 
caused by AβP(1–40) (line (a)), AβP(1–42) (line (c)), and AβP(25–35) (line (e)), no remarkable 
changes were induced by AβP(40–1), control peptide with no toxicity (line (b)). There is 
controversy over whether the AβP-induced [Ca2+]i changes occur through receptor-
mediated pathways or amyloid channels formed by direct incorporation of AβP. To clarify 
the precise characterization of the AβP-induced [Ca2+]i changes, we performed detailed and 
quantitative analysis of the AβP-induced Ca2+ influx using a high-resolution multi-site video 
imaging system. This multisite fluorometry system enables the simultaneous long-term 
observation of temporal changes in [Ca2+]i in more than 50 neurons. There are 5 major pieces 
of evidence supporting the hypothesis that AßP-induced [Ca2+]i changes occur through 
amyloid channels. First, the AβP-induced [Ca2+]i rise was highly heterogeneous among 
genetically identical GT1-7 cells. Even in the same field of view, exposure to the same 
peptide solution produced differential changes in the [Ca2+]i levels (Fig. 4A). Considering 
the heterogeneity, we compared the peak increase in [Ca2+]i (∆[Ca2+]i) induced by AβPs, and 
its latency (the lag between the [Ca2+]i increase and the time of AβP addition) in each cell to 
quantitatively analyze Ca2+ influx. 
Although AβP (1–40) induced an increase in [Ca2+]i levels either instantly or after some 
delay, the magnitude and latency differed. In addition, some adjacent cells still did not 
exhibit any responses. Second, the average ∆[Ca2+]i was increased and the average latency 
was shortened in a dose-dependent manner (Fig. 4B and C). These features are considerably 
similar to those observed in relation to toxic peptide channels formed on membranes. Third, 
the AβP-induced increase in [Ca2+]i was not influenced by the addition of a Na+ channel 
blocker (tetrodotoxin), a Ca2+ channel blocker (nifedipine), a glutamate receptor antagonist 
(D-APV), or a γ-aminobutyric acid (GABA) antagonist (bicuculline). However, antibodies to 
AβP remarkably inhibited the [Ca2+]i increase resulting from AβP (Kawahara, 2004). Fourth, 
D-AβP(1–40), AβP(1–40) composed of D-amino acid residues, also caused the elevation of 
[Ca2+]i in a manner similar to AβP(1–40) (see Fig. 3, line (d)). Fifth, the vulnerability of 
primary cultured rat hippocampal neurons to AβP was changed during the culture period, 
despite that the expression and the function of neurotransmitter are not changed (Kato-
Negishi and Kawahara, 2008). On the basis of these lines of evidence, we conclude that AβP 
causes the disruption of Ca2+ homeostasis via the formation of amyloid channels in 
membranes, ultimately resulting in neuronal death. 
Pore formation-induced cytotoxicity is commonly observed in our biological system, 
particularly in the presence of certain toxins and venoms including the α-toxin of 
Staphylococcus aureus, magainin 2, a 26-residue antimicrobial peptide obtained from 
Xenopus laevis, melitin, a bee venom composed of 28 amino acids, or antibiotics such as 
amphotericin and gramicidin (Bechinger, 1997). In this respect, AβPs may share the 
similar toxicity mechanism as various antimicrobial or antifungal peptides that exhibit 
pore-forming ability and cell toxicity. Indeed, Soscia et al. demonstrated that AβP exerts 
antimicrobial activity against 8 common and clinically relevant microorganisms (Soscia et 
al., 2010). 
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Fig. 3. Characteristics of the elevations in [Ca2+]i induced by AβP and other amyloidogenic 
proteins. Typical time course of [Ca2+]i at 2 min prior to and at 3 min after the application of 
the peptide is depicted. (a) AßP(1-40); (b) AßP(40-1); (c) AßP(1-42); (d) D-AßP(1-40);  
(e) PrP106-126; (f) scramble PrP106-126; (g) human amylin; (h) rat amylin; (i) NAC; and  
(j) magainin 2. All peptides were at 10 µM. The arrow indicates the time of peptide addition 
Recently, a new concept of “conformational disease,” had been proposed, suggesting that 
the conformation of disease-related proteins (amyloidogenic proteins) is an important 
determinant of their toxicity, and consequently, the disease development (Carrell and 
Lomas, 1997). The conformational diseases includes prion diseases, triplet-repeat diseases, 
e.g., Huntington’s disease, Parkinson’s disease and other neurodegenerative diseases that 
can be categorized under dementia with Lewy bodies (DLB). Increasing evidence indicates 
that most of these disease-related amyloidogenic proteins or their peptide fragments are 
directly incorporated into membranes to form ion channels as well as AβP (Lashuel and 
Lansbury, 2002; Kawahara et al., 2011b). It was also demonstrated that AßP (1–40), α-
synuclein, amylin, ABri, or other amyloidogenic peptides morphologically similar common 
ion channel-like structures and elicit single channel currents using AFM, CD, gel 
electrophoresis, and electrophysiological recordings (Quist et al., 2005; Lal et al., 2007).  
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We have also demonstrated that these amyloidogenic peptides including PrP106–126 (a 
peptide fragment of prion protein), human amylin, NAC, or antimicrobial peptide 
magainin2 also caused an elevation in the [Ca2+]i levels similar to that induced by AβPs 
(Kawahara et al., 2000; Kawahara, 2004). However, rat amylin and a peptide a randomized 
PrP106–126 sequence (scrambled PrP106–126) did not induce any [Ca2+]i changes (Fig. 3). 
We have also demonstrated that PrP106-126 forms β-sheet structures and exhibits 
neurotoxicity as well as AβP (Kawahara et al., 2011a). In addition, oligomeric α-synuclein 
causes neuronal death via the Ca2+ influx (Danzer et al., 2007). Considering these results 
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Fig. 4. (A) Heterogeneity of AβP-induced changes in [Ca2+]i Temporal changes of 50 
randomly chosen GT1-7 cells in the same field of view before and after the exposure to 
AβP(1–40). The arrow indicates the time of peptide addition. B~C: The peak increase in 
[Ca2+]i (∆[Ca2+]i) in each cell and the latency after exposure to AβP (1–40) were analyzed (B) 
in more than 50 cultured neurons in a single field of view (360×420 µm3) (mean ± S.E.M., 
n=300). Typical responses of [Ca2+]i in cultured neurons following exposure to various 
concentrations of AβP (1–40) (2.5~10 µM). The peak increase in [Ca2+]i (∆[Ca2+]i) in each cell 
(C) and the latency (D) after exposure to AßP (1–40) 
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together, it is plausible that these disease-related amyloidogenic proteins share similarities 
in channel formation and the disruption of Ca2+ homeostasis as well as β-sheet formation 
and cytotoxicity. Table 1 summarizes the common properties of these proteins.  
 
Disease Amyloidogenic protein or its fragment peptide  
and the primary sequence 
ß-sheet 
formation 
Cytotoxicity Channel 
formation 
Morphol
ogical 
pores 
[Ca2+]i 
rise 
Alzheimer’s disease AßP(1-40) 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGL
MVGGVV 
AßP(40-1) 
VVGGVMLGIIAGKNSGVDEAFFVLKQHHVEYGS
DHRFEAD 
AßP(25-35) 
DVGSNKGAII 
AßP(1-42) 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGL
MVGGVVIA 
 
+ 
 
– 
 
+ 
 
+ 
 
+ 
 
– 
 
+ 
 
+ 
 
+ 
 
– 
 
+ 
 
+ 
 
+ 
 
n.d. 
 
+ 
 
n.d. 
 
+ 
 
– 
 
+ 
 
+ 
Prion disease PrP106-126 (prion protein fragment) 
   KTNMKHMAGAAAAGAVVGGLG 
Scramble PrP106-126 
   NGAKALMGGHGATKVMVGAAA 
 
+ 
 
– 
 
+ 
 
– 
 
+ 
 
– 
 
n.d. 
 
+ 
 
– 
Parkinson’s disease 
(DLB; diseases with 
Lewy bodies) 
α-synuclein 
NAC ( α fragment of α-synuclein ) 
EQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFV 
 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
Triplet-repeat disease Polyglutamine 
   QQQQQQQQ------------------- + + + 
 
n.d. 
 
n.d. 
Familial British 
dementia 
ABri35 
ASNCPAIRHPGNKPAVGTLICSRTVKKNIIGGN + + + + 
 
n.d. 
Diabetes mellitus Human amylin 
KCNTATCATQRLANFLVHSSNNFGAILSSTNVGS
NTY 
Rat amylin 
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGS
NTY 
+ 
 – 
+ 
 – 
+ 
 – 
+ 
 
 
+ 
 – 
Medullary carcinoma 
of the thyroid 
Calcitonin 
CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP + + + + +  
n.d.: not determined  
Table 1. Characteristics of amyloidogenic proteins and the related peptides 
6. Possible candidates for the treatment of AD 
The search for protective agents against AβP-induced neurotoxicity is of great importance. 
Substances that prevent the oligomerization of AβP such as rifampicin, curcumin, aspirin, 
DHA can be potential candidates against AβP neurotoxicity (Fig. 2). Reduction of AβP 
production using BACE or γ-secretase inhibitors is reportedly effective for the treatment of 
AD. In addition, even though AβP vaccines had been associated with adverse effects, they 
may be considered as a potential treatment alternative. Conversely, trace metals such as Al, 
Zn, and Cu enhance AβP oligomerization; thus, chelation therapy with clioquinol, 
deferoxamine, or silicates has been proposed to be effective in the treatment of AD (Lannfelt 
et al., 2008; Exley, 2007).  
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Here, we focused on substances that inhibit the formation of amyloid channels. As 
discussed, the elevation of [Ca2+]i by its permeation through amyloid channels is considered 
to be the primary event of AβP-induced neurotoxicity; therefore, such compounds could 
serve as the foundation for the new and effective drugs with fewer adverse effects. 
Inorganic cations such as Zn2+ inhibit the current induced by amyloid channels. Zn is 
abundant in presynaptic terminal vesicles and is secreted into synaptic clefts following 
neuronal excitation. Considering that Zn binds to the His residues of AβP, Arispe et al. 
found that His-related peptide derivatives, such as His-His, effectively inhibit the current 
through amyloid channels, attenuate AβP-induced [Ca2+]i changes, and protect neurons 
from AβP toxicity (Arispe et al., 2008). They also developed new compounds with 
pyrimidine structures that inhibit the amyloid channels and investigated its efficacy for 
treatment (Diaz et al., 2009, Arispe et al., 2010).  
We focused substances which modify the membrane properties and inhibit amyloid 
channels. It is widely accepted that the composition of membrane lipids strongly influences 
the direct incorporation of peptides into membranes and consequent channel formation 
(Bechinger and Lohner, 2006; Simakova & Arispe, 2007). In particular, electrostatic 
interactions between peptides and lipids, namely, the net charges of the membrane surface, 
and membrane fluidity play crucial roles in the affinity for peptides (Seelig et al., 1994). 
Several AβP residues (e.g., Arg5, Lys16, and Lys28 residues) have a positive charge at a 
neutral pH; thus, AβP has an affinity for negatively charged phospholipids, such as 
phosphatidylserine (PS) or phoshatidylglycerol (PG), but not for neutral phospholipids such 
as phosphatidylcholine (PC). The formation of ß-sheet structures by AβP (1–40) was 
increased after the addition of PG. Meanwhile, substances that decrease membrane fluidity 
are known to enhance membrane stiffness and influence pore formation by toxins (Tomita et 
al., 1992). Gangliosides also contribute to the net charge of the outer membrane surface and 
to the binding to AβPs. Micro-circumstances on the membranes, such as rafts, containing 
gangliosides and cholesterol, may provide suitable locations that facilitate this process 
(Matsuzaki et al., 2010). Indeed, disruption of raft protected neurons from AβPs-induced 
neurotoxicity (Malchiodi-Albedi et al., 2010).  
Thus, we have developed a screening system for compounds that influence membrane 
properties by observing the AβP-induced influx of Ca2+. Among tested, we demonstrated 
that several lipophilic substances such as phloretin, cholesterol, 17β-estradiol, 17α-estradiol, 
and neurosteroids including dehydroepiandrosterone (DHEA), DHEA sulfate (DHEA-S), 
and pregnenolone, significantly inhibit AβP-induced [Ca2+]i elevation (Kawahara and 
Kuroda, 2001, Kato-Negishi and Kawahara, 2008). Figure 5 exhibits the structures of these 
compounds. 
Phloretin, a plant-derived flavonoid, decreases the membrane potential and inhibits the 
electrostatic interaction between AβP and membrane lipids (Hertel et al., 1997). Cholesterol 
decreases membrane fluidity and inhibits channel formation by peptides such as α-toxin, 
gramicidine, amylin, and AβP. The pretreatment with phloretin or cholesterol significantly 
inhibited the AßP-induced increase in [Ca2+]i in cultured neurons. Meanwhile,  
6-ketocholestanol, which increases the membrane dipole potential, did not influence the 
AβP-induced increase in [Ca2+]i .  
Furthermore, 17β-estradiol, a female hormone, is neuroprotective and affects membrane 
fluidity (Schwartz et al., 1996). Considering that both of 17β-estradiol and 17α-estradiol 
inhibit the AβP-induced [Ca2+]i elevation, this inhibition may depend on their membrane 
modifying effects (Whiting et al, 2000). All of these compounds inhibit AβP neurotoxicity. 
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Fig. 5. Chemical structures of substances which influence AβP-induced [Ca2+]i elevation 
Neurosteroids are steroid hormones synthesized de novo in the central nervous system from 
cholesterol or from peripheral steroid precursors (Tsutuki et al., 2000). Several lines of 
evidence suggest that neurosteroids modulate various functions of the brain and exhibit 
neuroprotective activitiy (Mellon, 2007). Thus, neurosteroids have been recognized as anti- 
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aging hormones, and are widely used as supplements to improve the impaired cognitive 
functions of the elderly (Huppert et al., 2000). Considering that plasma DHEA-S levels are 
reduced in healthy individuals in an age-dependent manner and in AD patients (Hillen et 
al., 2000; Aldred and Mecocci, 2010), neurosteroids may have an important role in the 
pathogenesis of AD. 
7. Amyloid channel hypothesis 
Considering the results of our study together with those of the others, we propose the 
following hypothetical scheme of AβP-induced neurodegeneration (Fig. 6). 
AβPs are normally secreted following the cleavage of APP in the synaptic compartment into 
the cerebrospinal fluid. The secreted AβPs are usually degraded proteolytically within a 
short period. However, the upregulation of AβP secretion from APP, or an increased ratio of 
AβP(1–42) to AβP(1–40), which are influenced by APP or presenilin gene mutations, may 
facilitate the retention of AβP in the brain.  
As descried previously, the net charge of the outer membrane surface may be a 
determinant when secreted AβPs bind to cellular membranes. The distribution of 
phospholipids on cellular membranes is usually asymmetrical; neutral lipids such as PC 
usually exist on the outer surface of plasma membranes, whereas negatively charged 
phospholipids such as PS exist on the inner membrane surface. When this asymmetric 
distribution is disrupted by apoptotic conditions or aging, AβPs can bind to the membrane 
surfaces (Fig. 6, step (A)). After incorporation into the membrane, the conformation of 
AβPs change and the accumulated AβPs aggregate on the membranes. The ratio of 
cholesterol to phospholipids in the membrane may alter membrane fluidity, thereby 
affecting the process from step (A) to (B). Considering that apoE, its phenotype is a risk 
factor of AD, is a cholesterol-binding protein, the relationship between cholesterol and AD 
is important in the pathogenesis of AD.  
Finally, aggregated AβP oligomers form ion channels (Fig. 6 (C)), leading to the various 
neurodegenerative processes. Once AβP channels are formed in neuronal membranes, the 
homeostasis of Ca2+ and other ions is disrupted. Unlike endogenous Ca2+ channels, these 
AβP channels are not regulated by the usual channel blockers; thus, once formed on the 
membrane, a continuous flow of Ca2+ is initiated. However, Zn2+ ions, which are secreted 
into the synaptic cleft in a neuronal activity-dependent manner, inhibit AβP-induced Ca2+ 
entry, and thus have a protective function in AD. Disruption of Ca2+ homeostasis triggers 
several apoptotic pathways and promotes numerous degenerative processes, including free 
radical formation and tau phosphorylation, thereby accelerating neuronal death. Presenilins 
can influence Ca2+ homeostasis through the disturbances of the capacitive Ca2+ entry or 
other pathways, and may influence these pathways. Free radicals also induce membrane 
disruption, by which further amplifies unregulated Ca2+ influx. The disruption of Ca2+ 
homeostasis influences the production and processing of APP. Thus, a vicious cycle of 
neurodegeneration is initiated. 
The velocity of channel formation will be regulated by the binding of AßP on membranes 
and its concentration, considering that in vitro aging can enhance the neurotoxicity of AβP 
and natural oligomers (dimmers or trimers) are more toxic as compared to monomers, it is 
provable that AßP oligomerization in vitro accelerates the velocity from (A) to (B), and 
enhances the formation of tetrameric or hexameric pores on membranes. These oligomers 
might easily form tetrameric or hexameric pores and exhibit neurotoxicity. Indeed, O'Nuallain  
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Fig. 6. Hypothesis concerning amyloid channels in the pathogenesis of Alzheimer’s disease. 
AβPs are secreted from into synapses following the cleavage of APP, and then directly 
incorporated into membranes. The hypothetical scheme for the formation of oligomeric 
amyloid channels is depicted. Details are shown in the text 
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et al. demonstrated that AßP dimmers formed toxic protofibrils more rapidly compared to 
monomer (O'Nuallain et al., 2010). In spite that the exposure to relatively high concentration 
of AβP in vitro causes the acute elevation of [Ca2+]i and exhibits neurotoxicity, the 
concentration of the AβP are low and it is difficult to bind to outer membranes. Thus, the 
processes required for channel formation (from steps (A) to (C)) in our brains may require a 
long life span and determine the rate of the entire process. This amyloid channel hypothesis 
explains the long delay in AD development; AD occurs only in aged subjects despite the fact 
that AβPs are normally secreted in younger or normal subjects. Various environmental 
factors, such as foods or trace metals, as well as genetic factors will influence these processes 
and contribute to AD pathogenesis.  
8. Conclusion 
Despite the immense efforts to develop a therapeutic drug for AD, the results have not been 
satisfactory. However, we believe that if we can understand the precise pathogenic 
mechanism more clearly, then potential therapeutic drugs (such as supplements) will be 
developed in the future. The amyloid channel hypothesis may improve the precise 
understanding of AD and the development of drugs for AD treatment. Further, it might be 
worthwhile to consider the application of dietary supplements such as estrogen or 
neurosteroids for the prevention of AD. Our efforts in developing new drugs will certainly 
be fruitful for the economy of the nation and the health of the population. 
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